The Filing Desk

Absci vs Humacyte

Absci ABSI · Humacyte HUMA · Biotechnology

Absci reported revenue of $3 million in fiscal 2025, 1.4 times Humacyte's $2 million in fiscal 2025. Absci had an operating margin of -4297.0%, against -5306.0% at Humacyte. Free cash flow was −$94 million at Absci and −$106 million at Humacyte.

Side by side

AbsciHumacyte
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$3M$2M
Revenue growth−38.2%—
Revenue growth a year, last 5 years−10.2%—
Gross margin—−376.1%
Operating margin−4,297.0%−5,306.0%
Net margin−4,113.7%−2,003.6%
Free cash flow−$94M−$106M
Free cash flow margin−3,358.3%−5,197.6%
Return on capital−162.8%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count24.1%33.5%
Last close$8.16$0.54
P/E at the last close——
Insider trades, last 12 monthsbought $933,174, sold $132,328bought $89,990, sold $41,298
Piotroski F-score3 of 83 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AbsciHumacyte
Operating margin
Percent of revenue
AbsciHumacyte
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AbsciHumacyte

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Absci and Humacyte pages.